Telemonitoring for Heart Failure Evidence & Practice Professor John G.F. Cleland Department of Cardiology, Hull York Medical School University of Hull Kingston-upon-Hull UK Conflict of Interest: I have received honoraria and/or research support from Philips, Bosch, GE, Alere and St Jude
26
Embed
Telemonitoring for Heart Failure Evidence & Practice
Telemonitoring for Heart Failure Evidence & Practice. Professor John G.F. Cleland Department of Cardiology, Hull Y o rk Medical School University of Hull Kingston-upon-Hull UK. Conflict of Interest: I have received honoraria and/or research support from Philips, Bosch, GE, Alere and St Jude. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Telemonitoring for Heart Failure
Evidence & Practice
Professor John G.F. ClelandDepartment of Cardiology,Hull York Medical School
University of HullKingston-upon-Hull
UK
Conflict of Interest: I have received honoraria and/or research support from Philips, Bosch, GE, Alere and St Jude
• Audit
0.0
00.2
50.5
00.7
51.0
0C
um
ula
tive
su
rviv
al
0 90 180 270 360Survival time (days)
55-64 years 65-74 years75-84 years >=85 years
Survival of Patients with a Primary Discharge Diagnosis of Heart FailureEngland & Wales 2009-2010
About 1 million people affected in the UK~450,000 admissions per year (65,000 in first
diagnostic position) N = 19,240 (about 30% of all expected cases)
Median age 79 years<65 years ~3,000 65-75 years ~4,00075-85 years ~7,000>85 years ~5,000
Cleland et alHEART 2011
TeleHealthWhy is it Likely to Become Essential?
1. More patients with long-term conditions– More older people– Longer survival with illness– Better primary & secondary prevention
2. Fewer professionals to provide health-care– Smaller proportion of population of working age– Loss of migrant workforce as economies rival UK– Better paid or more attractive / less stressful jobs
3. More monitoring required– Higher expected standards of care– More treatments that need to be monitored– More things that can be monitored
The Opportunity of Chronic Illness• Most patients soon learn routines
– Or have relatives / friends that do
• Most patients are interested in maintaining or improving their health
• Patients are an ‘inexpensive’ but neglected health-care provider opportunity
• Invest in patients– Education– Active Partnership– Empowerment
Re-admission
Duration of adm.
Mortality Patient Experience
Costs of care
Titration of therapy
Compliance
Detection of exacerbation
Cause of exacerbation
Treatment of WHF
Selection for Admission
Discharge planning
Patient Reassurance
TeleHealth - What Might it Achieve?
UltimateIntermediate
TEN-HMSThe Trans-European Network–Home-Care Management System
Patients about to be discharged from hospital after an exacerbation of chronic heart failure
(Published JACC 2005)
54% of Patients Aged >70 years
p < 0,05
Mo
rtal
ity
Cleland et al JACC 2005
TEN-HMS
Reduction in MortalityNTS or HTM v UCAbsolute 16.4%Relative 36 %
No reduction in hospitalisation
Shortening of hospital stay with HTM
TEN-HMS
48.9%
38.9%
7.8%3.3%
1.1%
much safer
safer no change
more anxious
much more
anxious
“ How do you feel about your health since receiving Telemonitoring? “
Undef.
TEN-HMS
50556065707580859095
100
ACEi BB Spirono . ACEi BB Spirono
UCNTSHTM
120 Days 240 Days
%
******
***
*** differences between HTM and other groups. No difference between UC and NTS
Achieving Therapeutic Target
0
10
20
30
40
50
60
70
I/II III IV or Dead240 Days
Patient Clinical Status
TEN-HMS: Total Patient Contacts
0
10
20
30
40
50
60
70
80
UC NTS HTM
Telephone Contact
Office Visits
Home Visits
Hospitalisation
Contacts Per 1,000 Days Alive and Out of Hospital
#
# under-reporting of events likely in this group P<0.01 HTM v NTS
Structured Telephone Supportn = 5,563
(Cochrane Review)
Mortality
Inglis et al 2010
HR 0.88 (0.76-1.01); p=0.08
All-Cause Hospitalisation
HR 0.77 (0.68-0.87.01); p<0.0001
New Trials• Tele-HF• TEHAF
Home Telemonitoringn = 2,710
(Cochrane Review)
Inglis et al 2010
Mortality
HR 0.66 (0.54-0.87); p<0.0001
All-Cause Hospitalisation
HR 0.91 (0.84-0.99); p=0.02
New Trials• TIM-HF• COMPASS• CHAMPION• SENSE-HF
Major Problems with RCTs of Service Delivery
• Technology differs– Telephone Support including Voice Activated Systems– Physiological telemonitoring
• Implanted or Not
• Care usually improves if it is the focus of attention– Effect in control group– Beware: “before v after” comparisons
• Lack of integration into existing services– Puts innovative interventions at a disadvantage
• Selection of patients at low risk with modern treatment
Percent of Days Lost To Hospitalisation or Death
5.8 5
1.1 1.32 2.1
0
5
10
15
20
25
30
35
40
UC NTS HTM
Death WHF Hosp Other Hosp
8.9% 8.4%
32.9
16.4 18.5
2.4
2.31.9
1.7
2.6 2.1
0
5
10
15
20
25
30
35
40
UC NTS HTM
Death WHF Hosp Other Hosp
37.0% 21.3% 22.6%
TEN-HMS (15 months) TIM-HF (26 months)
3.1 4.5
0.5 0.4
0.9 1.2
0
5
10
15
20
25
30
35
40
UC NTS HTM
Death WHF Hosp Other Hosp
TEHAF (12 months)
4.5% 6.1%
What Have We Done for TeleHealth in Hull?
• Established – International reference site (LifeLab) for HF epidemiology & research– International reputation for research excellence in telehealth– A model telehealth service
• Grants– TEN-HMS– Four FP7 grants relating to telehealth & heart failure– EDRF
• Industry Partnerships– Philips, GE, Bosch, Cardiomems, St Jude + others
• Publications– >500 PubMed citations in related fields– TEN-HMS, Concept Papers, Editorials– Systematic Reviews (EJHF, BMJ & Cochrane)
Services for Patients with Heart FailureThe Kingston-upon-Hull Model
Specialist ClinicsFamily Doctor(NT-proBNP)
Hull Telemonitoring ServiceOutcomes Compared to Historical Data, Surveys & Trials
0
5
10
15
20
25
30
35
40
Observed
HEY 2007
Surveys
Trials£311,573
£224,416
£87,157
£0
£50,000
£100,000
£150,000
£200,000
£250,000
£300,000
£350,000
Total gross savingsTotal service cost
Total net savings
Cost-Effectiveness of TeleHealth (Hull)
Where Next?
• Interactive TV
• New monitoring technologies
• Implanted devices
• More intelligent use of the patient data
• Investing in patients as health-care providers
Centre for Telehealth
The Hull Heart Failure Life-Lab30,000 patient-years of follow-up
Largest, Longest Follow-up, Epidemiologically-Representative Cohort of Heart Failure in the World
Rich in phenotyping, serial biomarker and outcome data
100
101
101
102
0
10
20
30
40
50
CRP (mg/L)
NT-proBNP (pmol/L)
Pro
ba
bili
ty o
f D
ea
th (
%)
0
5
10
15
20
25
30
35
40
45
50
• Shift from crisis detection to health maintenance
• Health Maintenance Envelope– More ‘optimistic’– Better way to engage/motivate patients– More active management– More activity likely to hold ‘actors’ attention– Clinical calibration– Addresses the issue of false alerts